Jun. 24 at 6:50 PM
$ARDX Compare this 2 small biotech in the same field dealing with TDAPA bundles. When we were at
$10 and
$2 Bn MC in 2024 AKBA was struggling at below
$1 MC @150 M. They got only one drug approved by FDA but they know they are a small player and could not afford to fight against the mighty CMS even they never like the TDAPA program but they went in first and lobbied later for better solutions. Nothing easy. The Street and investors recognized that & rewarded them nicely.
Raab’s bad and costly decision by not going into TDAPA has put a huge overhang on our SP since July 1st 2024 while losing valuable patent time. facts and results have spoken loud and clear. Change the direction and reapply to TDAPA if nothing good comes out from legislation or legality ends by yr end. That would put us back to
$8S ranges.
AKBA has shown us that Raab is wrong but we can fix that. Fighting against mighty fed is never a good idea. We are here to make max money possible. Let BP fight the CMS war.
